Sonoma stock: buy or sell?

SNOA stock price: $0.79 0.00% At close on May 21st, 2019

Updated on:
May 21st, 2019


Sonoma Pharmaceuticals ended today at $0.79 and stayed constant a neutral 0.00%.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally.

Should I buy Sonoma stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Sonoma stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Sonoma stock a buy?

Banks and financial institutions publish stock ratings everyday. Unfortunately, we couldn't detect any rating for SNOA stock for the last 30 days.

Sonoma stock analysis

Daily outlook

Sonoma stayed constant a neutral 0.00% and closed at $0.79.

Sonoma Pharmaceuticals shares stayed constant 0.00% to $0.79 today. Since last March when SMA50d and SMA100d crossed up, SNOA price slipped $-0.15 per share (-15.96%).

SNOA stock chart (daily)

Weekly outlook

After sliding a scary -6.10% in a week last week, Sonoma Pharmaceuticals closed this week at $0.79 and slipped a godawful -3.66%. This was the third red week in a row, sliding in full a -11.63%. Early April SNOA rocketed a wonderful 5.05% in just one week.

Observing the weekly chart, price is in a simple uptrend, tested $0.80 level and now climbing back aiming its last top at $1.15. Since price and 20-weeks moving average lines crossed down last week, SNOA fell $-0.08 per share (-9.20%). Since mid March when SMA10w and SMA20w crossed up, SNOA price slipped $-0.21 per share (-21.00%).

SNOA stock chart (weekly)

Sonoma stock price history

Sonoma IPO was on January 25th, 2007 at $271.25 per share1. Since then, SNOA stock lost a -99.70%, with a yearly average of -8.30%.

1: Adjusted price after possible price splits or reverse-splits.

Sonoma stock historical price chart

SNOA stock reached 52-week highs on June at $4.10, and all-time highs 2007-07-17 with a price of 401.8.

Sonoma stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' SNOA stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price target for Sonoma stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Sonoma reported its latest financial data, posting a cool climb for the Earnings per Share (EPS) ratio. Experts expected $-0.21 per share, but Sonoma posted $-0.26.
SNOA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Sonoma Pharmaceuticals annual turnover rocketed an amazing 29.89% to $16.66 million dollars from $12.83 marked in 2017. Nonetheless, its profit margin (compared to sales) plunged to -86.01%, that is $-14.33 million.

To have an updated view of the financial situation of Sonoma, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Sonoma TTM sales up to December 2018 were $18.24 and income was $-13.34 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Sonoma Pharmaceuticals business evolution since March 2018: Annual turnover up to December, compared to lastest yearly report, rose a phenomenal 9.51%. Regarding profit margin, Sonoma skyrocketed 12.89% to -86.01%

SNOA annual Sales and Income evolution
2013$15 M-$-5.43 M-35.1%-
2014$14 M-11.52%$3.74 M27.4%-168.88%
2015$14 M1.35%$-8.20 M-59.2%-319.33%
2016$15 M8.88%$-10.16 M-67.4%23.88%
2017$13 M-14.98%$9.27 M72.3%-191.26%
2018$17 M29.89%$-14.33 M-86.0%-254.50%
TTM $18 M9.51%$-13.34 M-73.1%-6.90%

Quarterly financial results

Sonoma posted $5.28 M in sales for 2018-Q4, a 6.90% improvement compared to previous quarter. Reported quarter earnings marked $-2.30 M with a profit margin of -43.52%. Profit margin boosted a 13.57% compared to previous quarter when profit margin was -57.10%. When comparing sales to same quarter last year, Sonoma Pharmaceuticals sales marked a superb growth and jumped a 9.02%. Looking back to recent quarterly results, Sonoma Pharmaceuticals posted 3 negative quarters in a row.
SNOA quarterly Sales and Income evolution
2017-Q1$4 M-$-2.93 M-72.7%-
2017-Q2$4 M-4.71%$-3.51 M-91.4%19.80%
2017-Q3$4 M12.63%$-2.87 M-66.4%-18.23%
2017-Q4$5 M11.98%$-3.19 M-65.8%11.05%
2018-Q1$4 M-24.53%$-4.76 M-130.3%49.45%
2018-Q2$4 M19.53%$-3.46 M-79.1%-27.40%
2018-Q3$5 M13.05%$-2.82 M-57.1%-18.45%
2018-Q4$5 M6.90%$-2.30 M-43.5%-18.51%

Sonoma ownership

When you are planning to invest in shares of a stock, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Sonoma, 2.03% of all outstanding shares are owned by its staff.

In case of Sonoma Pharmaceuticals stock, 14.50% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SNOA stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related companies:

Market cap$9.5 M$4.3 B$226.2 M$339.0 M$6.0 M
Total shares12.0 M85.5 M33.8 M109.4 M17.2 M
Float shares11.7 M70.6 M32.9 M81.4 M5.3 M
  - Institutional holdings (%)14.5%85.1%124.2%20.8%4.1%
  - Insider holdings (%)2.0%17.3%3.5%2.6%25.9%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Sonoma summary

Tuesday, May 21st, 2019
Day range$0.76 - $0.80
Previous close$0.79
Session gain0.00%
Average true range$0.04
50d mov avg$0.92
100d mov avg$0.85
200d mov avg$1.12
Daily patternlt01c
Weekly pattern lb01a

Sonoma performance

To measure stock performance is always good to benchmark with competitors or related stocks. For Sonoma, the benchmark is made against Integra LifeSciences, Invacare, MiMedx, NovaBay Pharmaceuticals, ProPhase Labs and Teleflex.
SNOASonoma Pharmaceut...-12.22%-7.06%-79.59%
IARTIntegra LifeScien...-9.33%-6.29%-21.98%
NBYNovaBay Pharmaceu...-73.88%-71.07%-86.27%
PRPHProPhase Labs1.00%8.99%0.66%

Sonoma competitors

One check before investing in any stock is to review a list of its competitors, in this case for Sonoma Pharmaceuticals. We chose 6 companies as Sonoma Pharmaceuticals competitors as they are in the same industry or have similar market objectives.